Inhibikase Therapeutics Files S-1 Registration Statement

TL;DR

<b>Inhibikase Therapeutics, Inc. has filed an S-1 registration statement with the SEC, signaling potential future public offerings.</b>

AI Summary

Inhibikase Therapeutics, Inc. (IKT) filed a IPO Registration (S-1) with the SEC on April 19, 2024. Inhibikase Therapeutics, Inc. filed an S-1 registration statement with the SEC on April 19, 2024. The filing indicates the company is a smaller reporting company and an emerging growth company. The company's principal executive offices are located at 3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA 30339. The filing is for a registration statement under the Securities Act of 1933. The company's IRS Employer Identification Number is 26-3407249.

Why It Matters

For investors and stakeholders tracking Inhibikase Therapeutics, Inc., this filing contains several important signals. This S-1 filing is a prerequisite for the company to offer its securities to the public, potentially raising capital for its operations and drug development. As a smaller reporting and emerging growth company, Inhibikase may benefit from certain regulatory accommodations, but it also suggests a company with a smaller market capitalization and potentially less established financial history.

Risk Assessment

Risk Level: low — Inhibikase Therapeutics, Inc. shows low risk based on this filing. The risk is low as this is a standard S-1 filing for a company preparing for potential public offerings, with no immediate negative financial or operational disclosures.

Analyst Insight

Monitor future filings for details on the proposed offering, including the number of shares, price range, and use of proceeds.

Key Numbers

• 2024-04-19 — Filing Date (Date the S-1 registration statement was filed)
• 263407249 — IRS Number (Company's IRS Employer Identification Number)
• 333-278844 — SEC File Number (SEC registration file number)
• 2836 — SIC Code (Standard Industrial Classification Code for Biological Products)

Key Players & Entities

• Inhibikase Therapeutics, Inc. (company) — Registrant name
• Milton H. Werner, Ph.D. (person) — President and Chief Executive Officer
• McDermott Will & Emery LLP (company) — Legal counsel
• Thompson Hine LLP (company) — Legal counsel
• Atlanta, GA (location) — Business address
• 263407249 (other) — IRS Employer Identification Number
• 333-278844 (other) — SEC File Number

FAQ

Industry Context

Inhibikase Therapeutics operates in the biotechnology sector, focusing on the development of therapeutics. The S-1 filing is a standard step for companies in this industry looking to access public capital markets.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States.

What Investors Should Do

1. Review the full S-1 filing for detailed business descriptions, risk factors, and financial information.
2. Track subsequent SEC filings (e.g., 424B filings) for details on any actual public offering.
3. Analyze the company's clinical pipeline and target indications mentioned in the S-1.

Key Dates

• 2024-04-19: S-1 Filing — Registration statement filed with the SEC, indicating intent for public securities offering.

Year-Over-Year Comparison

This is an initial S-1 filing, so there is no prior filing of this type to compare against for 'vs last filing' data.

Key Financial Figures

• $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr
• $0.0001 — e of each pre-funded warrant will equal $0.0001 per share of common stock. For each pre
• $100,000 — ees and expenses in the amount of up to $100,000, and for its clearing expenses in the a

Filing Documents

• d827405ds1.htm (S-1) — 421KB
• d827405dex1018.htm (EX-10.18) — 101KB
• d827405dex231.htm (EX-23.1) — 2KB
• d827405dexfilingfees.htm (EX-FILING FEES) — 33KB
• g827405g02a02.jpg (GRAPHIC) — 36KB
• 0001193125-24-103050.txt (&nbsp;) — 608KB

USE OF PROCEEDS

USE OF PROCEEDS 21

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 24

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 28

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 31 PLAN OF DISTRIBUTION 32 LEGAL MATTERS 39 EXPERTS 39 INFORMATION INCORPORATED BY REFERENCE 39 WHERE YOU CAN FIND MORE INFORMATION 40 Table of Contents ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with information other than the information that we have provided or incorporated by reference in this prospectus and your reliance on any unauthorized information or representation is at your own risk. This prospectus may be used only in jurisdictions where offers and sales of these securities are permitted. You should assume that the information contained in this prospectus is accurate only as of the date of this prospectus, and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or of any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since those dates. This prospectus contains market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. In addition, the market and industry data and forecasts that may be included in this prospectus may involve estimates, assumptions and other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading Risk Factors contained in this prospectus. Accordingly, investors should not place undue reliance on this information. The representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorpora

View Full Filing

View this S-1 filing on SEC EDGAR